子宫内膜癌分子分型相关的研究进展
Research Progress on Molecular Typing of Endometrial Carcinoma
DOI: 10.12677/ACM.2023.132360, PDF,   
作者: 李莹花, 祖菲娅·艾力*：新疆医科大学第一附属医院妇科，新疆 乌鲁木齐
关键词: 子宫内膜癌；分子分型；精准治疗；Endometrial Carcinoma； Molecular Typing； Accurate Treatment
摘要: 子宫内膜癌是常见的妇科肿瘤之一，分子生物学特征是肿瘤发生机制及治疗方法的研究热点，子宫内膜癌分子分型的提出为患者诊断、治疗及预后判断提供了有力依据。它的改良方法主要有前瞻性分子危险分类法(Proactive Molecular Risk Classifier for Endometrial Cancer, ProMisE)和Tans-PORTEC分型，这两种改良方法在临床工作中较为实用，患者通过分子分型可获得个体化的综合治疗方案。本文就分子分型相关的研究进展等进行综述。
Abstract: Endometrial carcinoma is one of the common gynecological tumors. Molecular biological character-istics are the research focus of tumorigenesis and treatment. The proposal of molecular classifica-tion of endometrial carcinoma provides a strong basis for diagnosis, treatment and prognosis of pa-tients. Its improved methods are mainly prospective molecular risk classification (Proactive Molec-ular Risk Classifier for Endometrial Cancer, ProMisE) and Tans-PORTEC typing. These two improved methods are more practical in clinical work, and individual comprehensive treatment can be ob-tained by molecular typing. The research progress related to molecular typing is reviewed in this paper.
文章引用：李莹花, 祖菲娅·艾力. 子宫内膜癌分子分型相关的研究进展[J]. 临床医学进展, 2023, 13(2): 2550-2556. https://doi.org/10.12677/ACM.2023.132360

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Barbari, S.R. and Shcherbakova, P.V. (2017) Replicative DNA Polymer-ase Defects in Human Cancers: Consequences, Mechanisms, and Implications for Therapy. DNA Repair (Amst), 56, 16-25. [Google Scholar] [CrossRef] [PubMed]
[3] 谢玲玲, 林荣春, 林仲秋. 《2020NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2020, 36(4): 333-339.
[4] Urick, M.E. and Bell, D.W. (2019) Clinical Actionability of Molecular Targets in Endometrial Cancer. Nature Reviews Cancer, 19, 510-521. [Google Scholar] [CrossRef] [PubMed]
[5] Hussein, Y.R. and Soslow, R.A. (2018) Molecular Insights into the Classification of High-Grade Endometrial Carcinoma. Pathology, 50, 151-161. [Google Scholar] [CrossRef] [PubMed]
[6] 赵路阳, 戴一博, 李立伟, 等. TCGA分子分型在子宫内膜 癌中的应用及其临床意义[J]. 中华妇产科杂志, 2021, 56(10): 697-704.
[7] Talhouk, A., Hoang, L.N., Mcconechy, M.K., et al. (2016) Molecular Classification of Endometrial Carcinoma on Diagnostic Specimens Is Highly Concordant with Final Hysterectomy: Earlier Prognostic Information to Guide Treatment. Gynecologic Oncology, 143, 46-53. [Google Scholar] [CrossRef] [PubMed]
[8] Talhouk, A., Mcconechy, M.K., Leung, S., et al. (2015) A Clini-cally Applicable Molecular-Based Classification for Endometrial Cancers. British Journal of Cancer, 113, 299-310. [Google Scholar] [CrossRef] [PubMed]
[9] Talhouk, A., Mcconechy, M.K., Leung, S., et al. (2017) Confirmation of ProMisE: A Simple, Genomics-Based Clinical Classifier for End-Ometrial Cancer. Cancer, 123, 802-813. [Google Scholar] [CrossRef] [PubMed]
[10] Kommoss, S., Mcconechy, M.K., Kommoss, F., et al. (2018) Final Valida-tion of the ProMisE Molecular Classifier for Endometrial Carcinoma in a Large Population-Based Case Series. Annals of Oncology, 29, 1180-1188. [Google Scholar] [CrossRef] [PubMed]
[11] Proctor, L., Pradhan, M., Leung, S., et al. (2017) Assessment of DNA Ploidy in the ProMisE Molecular Subgroups of Endometrial Cancer. Gynecologic Oncology, 146, 596-602. [Google Scholar] [CrossRef] [PubMed]
[12] McAlpine, J., Leon-Castillo, A. and Bosse, T. (2018) The Rise of a Novel Classification System for Endometrial Carcinoma; Integration of Molecular Subclasses. The Journal of Patholo-gy, 244, 538-549. [Google Scholar] [CrossRef] [PubMed]
[13] Stelloo, E., Nout, R.A., Osse, E.M., et al. (2016) Improved Risk Assess-ment by Integrating Molecular and Clinicopathological Factors in Earlystage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clinical Cancer Research, 22, 4215-4224. [Google Scholar] [CrossRef] 
[14] Stelloo, E., Bosse, T., Nout, R.A., et al. (2015) Refining Prognosis and Identifying Targetable Pathways for High-Risk Endometrial Cancer: A TransPORTEC Initiative. Modern Pathology, 28, 836-844. [Google Scholar] [CrossRef] [PubMed]
[15] Ma, X., Dong, L., Liu, X., Ou, K. and Yang, L. (2022) POLE/POLD1 Mutation and Tumor Immunotherapy. Journal of Experimental & Clinical Cancer Research, 41, Article No. 216. [Google Scholar] [CrossRef] [PubMed]
[16] Huvila, J., Orte, K., Vainio, P., et al. (2021) Molecular Subtype Diagnosis of Endometrial Carcinoma: Comparison of the Next-Generation Sequencing Panel and Proactive Mo-lecular Risk Classifier for Endometrial Cancer Classifier. Human Pathology, 111, 98-109. [Google Scholar] [CrossRef] [PubMed]
[17] Koh, W.J., Abu-Rustum, N.R., Bean, S., et al. (2018) Uterine Neoplasms, Version 1. 2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 16, 170-199. [Google Scholar] [CrossRef] [PubMed]
[18] Hashim, M., Tizen, N.M.S., et al. (2021) A Study of HER2 Expres-sion in Endometrial Carcinoma: A Single Centre Experience. The Pan African Medical Journal, 38, Article 200. [Google Scholar] [CrossRef] [PubMed]
[19] Ross, D.S., Devereaux, K.A., Jin, C., et al. (2022) Histo-pathologic Features and Molecular Genetic Landscape of HER2-Amplified Endometrial Carcinomas. Modern Pathology, 35, 962-971. [Google Scholar] [CrossRef] [PubMed]
[20] Buza, N. (2021) HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent in Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. International Journal of Gynecological Pathology, 40, 17-23. [Google Scholar] [CrossRef] 
[21] de Boer, S.M., Powell, M.E., Mileshkin, L., et al. (2019) Adjuvant Chemoradiotherapy versus Radiotherapy Alone in Women with High-Risk Endometrial Cancer (PORTEC-3): Patterns of Recurrence and Post-Hoc Survival Analysis of a Randomised Phase 3 Trial. The Lancet Oncology, 20, 1273-1285. [Google Scholar] [CrossRef] 
[22] van den Heerik, A., Horeweg, N., Nout, R.A., et al. (2020) PORTEC-4a: International Randomized Trial of Molecular Profile-Based Adjuvant Treatment for Women with High-Intermediate Risk Endometrial Cancer. International Journal of Gynecological Cancer, 30, 2002-2007. [Google Scholar] [CrossRef] [PubMed]
[23] Wortman, B.G., Bosse, T., Nout, R.A., et al. (2018) Molecu-lar-Integrated Risk Profile to Determine Adjuvant Radiotherapy in Endometrial Cancer: Evaluation of the Pilot Phase of the PORTEC-4a Trial. Gynecologic Oncology, 151, 69-75. [Google Scholar] [CrossRef] [PubMed]
[24] Chung, Y.S., Woo, H.Y., Lee, J.Y., et al. (2021) Mismatch Re-pair Status Influences Response to Fertility-Sparing Treatment of Endometrial Cancer. The American Journal of Obstet-rics and Gynecology, 224, 370.e1-370.e13. [Google Scholar] [CrossRef] [PubMed]
[25] Raffone, A., Catena, U., Travaglino, A., et al. (2021) Mismatch Repair-Deficiency Specifically Predicts Recurrence of Atypical Endometrial Hyperplasia and Early Endometrial Carcino-ma after Conservative Treatment: A Multi-Center Study. Gynecologic Oncology, 161, 795-801. [Google Scholar] [CrossRef] [PubMed]
[26] RAINBO Research Consortium (2022) Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features: The RAINBO Clinical Trial Program. International Journal of Gynecological Cancer, 33, 109-117. [Google Scholar] [CrossRef] [PubMed]
[27] Jamieson, A., Bosse, T. and McAlpine, J.N. (2021) The Emerging Role of Molecular Pathology in Directing the Systemic Treatment of Endometrial Cancer. Therapeutic Advances in Med-ical Oncology, 13, 1-14. [Google Scholar] [CrossRef] [PubMed]

为你推荐